Browsing Tag
EHA 2025
2 posts
Blueprint Medicines highlights long-term clinical and real-world data for Ayvakit at EHA and EAACI 2025
Blueprint Medicines presents strong long-term survival and safety data for Ayvakit in systemic mastocytosis at EHA and EAACI 2025. Explore the clinical and market impact.
June 13, 2025
Enliven Therapeutics’ ELVN-001 shows strong Phase 1 results in CML, with Phase 3 plans in 2026
ELVN-001 from Enliven Therapeutics shows 47% MMR in CML trial; see what this means for the stock outlook and future Phase 3 plans. Read more.
June 13, 2025